Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Max Topp, MD
Julius-Maximilians-Universität, Medizinische Klinik und Poliklinik II, Würzburg
Principal Investigator - Nicola Gökbuget, MD
Klinikum der Goethe Universität Frankfurt
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
39 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Chu D'Angers
Angers, France
- Hôpital de L'Hôtel Dieu
Nantes, France
- Hôpital Saint Louis
Paris, France
- Chu de Purpan
Toulouse, France
- Charité - Campus Benjamin Franklin
Berlin, Germany
- Klinikum Der Goethe Universität, Medizinische Klinik Ii
Frankfurt, Germany
- Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
- Medizinische Hochschule Hannover
Hanover, Germany
- Universitätsklinikum Schleswig-Holstein
Kiel, Germany
- Universitätsklinikum Münster
Münster, Germany
- Universitätsklinikum Tübingen
Tübingen, Germany
- Universitätsklinikum Ulm
Ulm, Germany
- Julius-Maximilians-Universität, Medizinische Klinik Und Poliklinik Ii
Würzburg, Germany
- Ospedali Riuniti Di Bergamo
Bergamo, Italy
- Azienda Ospedaliera Antonio Cardarelli
Naples, Italy
- Ospedali Riuniti "villa Sofia-Cervello"
Palermo, Italy
- Università la Sapienza Di Roma
Rome, Italy
- Azienda Ospedaliero-Universitaria
Turin, Italy
- Azienda Ospedaliera Di Verona
Verona, Italy
- Ico Hospital Germans Trias I Pujol
Badalona, Spain
- Hospital Clínic Servei D´hematologia
Barcelona, Spain
- Hospital 12 de Octubre
Madrid, Spain
- Hospital Universitario de Salamanca
Salamanca, Spain
- Hospital Universitario Virgen del Rocio
Seville, Spain
- University Hospitals Bristol Nhs
Bristol, United Kingdom
- Royal Free Hampstead Nhs Trust
London, United Kingdom
- the Christie Nhs Foundation Trust
Manchester, United Kingdom
- City of Hope
Duarte, California, United States
- University of California Los Angeles
Los Angeles, California, United States
- Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
- Rush University Medical Center
Chicago, Illinois, United States
- University of Chicago
Chicago, Illinois, United States
- Dana Farber Institute
Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Roswell Park Cancer Streets
Buffalo, New York, United States
- University of Pennsylvania
Philadelphia, Pennsylvania, United States
- University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2011
- Primary completion
- 31 Oct 2013
- Completion
- 31 Jan 2017
- Last update posted
- 18 Aug 2017
- Registered enrollment
- 225
- Registry id
- NCT01466179
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.